Pharnext presenteert gegevens tweede fase PXT864 op 9e Clinical Trials on Alzheimer’s Disease (CTAD) in San Diego
PARIJS–(BUSINESS WIRE)– Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), een Frans biofarmaceutisch bedrijf dat een geavanceerd portfolio op vlak van neurodegeneratieve ziekten ontwikkelt, presenteert resultaten van fase 2 van een klinisch onderzoek naar PXT864. Dit is een PLEODRUG® voor de behandeling van de ziekte van Alzheimer. De resultaten worden gepresenteerd op de negende editie van de conferentie Clinical Trials on Alzheimer’s Disease (CTAD), die van 8 tot 10 december 2016 plaatsvindt in San Diego.
Details zijn als volgt:
|
Datum |
Tijd |
Evenement |
||
| Vrijdag
9 december |
Postersessie 2, P2-12
Neurophysiological Effect of PXT864 in mild Alzheimer’s Disease Patients Presentator: Karim Bennys, MD, centrum voor geheugenonderzoek Universiteitsziekenhuis, Montpellier, Frankrijk |
|||
| Zaterdag
10 december |
7:30 am | Mondelinge sessie, OC 54
36 Weeks of Treatment with PXT864 in Mild Alzheimer’s disease: Results from the PLEODIAL Extension Study Presentator: René Goedkoop, MD, hoofd medische zaken, Pharnext, Issy-les-Moulineaux, Frankrijk |
Pharnext to Present Phase 2 Data From PXT864 at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, United States |
|||||||||||||||||
|
PARIJS–(BUSINESS WIRE)– Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced that Phase 2 clinical trial data related to PXT864, a PLEODRUG® developed for the treatment of Alzheimer’s disease (AD), will be presented at the 9 th Clinical Trials on Alzheimer’s Disease (CTAD) conference, December 8-10, 2016 in San Diego (United States). Details are as follows:
Safety and clinical efficacy of PXT864 were assessed in 45 treatment-naïve patients with mild AD in a multicenter, exploratory, single blind Phase 2 study (PLEODIAL-I). Three doses of PXT864 were administered for 4 weeks followed by 4 weeks of placebo and then a 4-week re-challenge with PXT864. Subjects were then invited to continue study treatment (same dose received in PLEODIAL-I) for a further 24 weeks in the PLEODIAL-II extension study. Patients were treated with PXT864 for 32 out of 36 weeks in the PLEODIAL-I and II studies, and were allowed to use donepezil 5 mg, if their condition warranted treatment with a symptomatic agent, during the last 12 weeks of the study. PXT864 is a novel synergic fixed combination of baclofen and acamprosate given orally as a capsule twice a day. PXT864 was developed to restore the disrupted excitatory – inhibitory balance in the brain of patients suffering from neurodegenerative diseases (disrupted by toxic factors such as Aβ oligomeric peptides in Alzheimer’s disease). PXT864’s most advanced target indication is Alzheimer’s disease. Development in other neurodegenerative diseases including Parkinson’s disease and amyotrophic lateral sclerosis (ALS) are also planned. About Alzheimer’s Disease About Pharnext The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com PLEODRUG® and PLEOTHERAPY® are registered trademarks by Pharnext. View source version on businesswire.com: http://www.businesswire.com/news/home/20161130005622/en/ Contacts Pharnext |
|||||||||||||||||